Amicogen Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
23,181
27,332
32,457
68,968
73,665
Cost of Goods Sold (COGS) incl. D&A
11,126
13,296
20,703
45,737
49,924
Gross Income
12,055
14,036
11,754
23,231
23,742
SG&A Expense
3,263
4,603
9,417
19,053
21,846
EBIT
8,792
9,433
2,337
4,178
1,896
Unusual Expense
14
507
74
-
3,925
Non Operating Income/Expense
156
165
1,131
112
253
Interest Expense
151
25
345
936
968
Pretax Income
8,992
9,388
3,296
3,462
4,943
Income Tax
1,417
1,875
538
615
1,367
Equity in Affiliates
-
-
219
945
-
Consolidated Net Income
7,575
7,513
2,538
1,903
3,575
Net Income
7,575
7,563
2,066
1,589
4,606
Net Income After Extraordinaries
7,575
7,563
2,066
1,589
4,606
Net Income Available to Common
7,575
7,563
2,066
1,589
4,606
EPS (Basic)
509.38
437.94
116.26
85.72
247.00
Basic Shares Outstanding
15
17
18
19
19
EPS (Diluted)
491.17
434.87
116.07
85.85
247.25
Diluted Shares Outstanding
15
17
18
19
19
EBITDA
9,775
10,716
4,754
9,453
9,293
Non-Operating Interest Income
180
322
99
109
120
Minority Interest Expense
-
50
473
314
1,030
Equity in Affiliates (Pretax)
-
-
-
-
1,813

About Amicogen

View Profile
Address
64 Dongbu-ro 1259 beon-gil
Jinju SG 52621
Korea, Republic Of
Employees -
Website http://www.amicogen.com
Updated 09/14/2018
Amicogen, Inc. engages in the development and marketing of enzyme products and functional food materials. Its products include specialty enzyme for pharmaceutical, food, feed and industrial; new bio-ingredient such as natural health ingredients for food, feed and cosmetics, finished products; and immunological products such as protein A resin, anticancer treatment vaccine based on B cell and mononuclear cell, and POCT immune diagnosis device using innovative C-ECL technology. It also engages in original equipment manufacturing and original development manufacturing of nutraceutical products.